Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

56.48 +0.48 (+0.86%)

Streaming Delayed Price Updated: 10:59 AM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Analyst Ratings for Xenon Pharmaceuticals ↗

August 29, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter:

Via Benzinga

4 Analysts Have This to Say About Xenon Pharmaceuticals ↗

August 11, 2022

Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:

Via Benzinga

What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals ↗

August 11, 2022

Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter:

Via Benzinga

Xenon Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For Xenon Pharmaceuticals ↗

August 08, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.

Via Benzinga

The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise ↗

June 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency ↗

June 23, 2022

Via Benzinga

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering ↗

June 22, 2022

Via Benzinga

Recap: Xenon Pharmaceuticals Q1 Earnings ↗

May 10, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For August 9, 2022 ↗

August 09, 2022

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022 ↗

July 21, 2022

Upgrades

Via Benzinga

Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All ↗

June 23, 2022

The company had bullish results in seizure treatment. But it wasn't enough.

Via Investor's Business Daily

US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony ↗

June 23, 2022

Pre-open movers

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Looking Into Xenon Pharmaceuticals's Return On Capital Employed ↗

June 13, 2022

According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67...

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For May 10, 2022 ↗

May 10, 2022

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

Via Benzinga

Swing Trading Stock Watchlist For April 11 And Beyond ↗

April 10, 2022

The stock market's health is neutral. It is not bad, but it is not great either. I’m willing to take long trades in the stocks discussed if they form valid trade setups and trigger, but I’m not being...

Via Talk Markets

Swing Trading Stock Watchlist For April 4 And Beyond ↗

April 03, 2022

The stock market's health has improved. That means I have the green light to buy stocks that are forming quality trade setups. Let's dive into what I have been looking at this week.

Via Talk Markets

Xenon Pharmaceuticals's Return On Capital Employed Overview ↗

March 07, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) brought in sales totaling $3.74 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 65.52%, resulting in...

Via Benzinga

Recap: Xenon Pharmaceuticals Q4 Earnings ↗

March 01, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Xenon Pharmaceuticals's Earnings: A Preview ↗

February 28, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement....

Via Benzinga

Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine ↗

January 12, 2022

Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory...

Via Benzinga

Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech ↗

December 29, 2021

For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chi...

Via Benzinga

Xenon Pharmaceuticals Scores As Epilepsy Results Highlight 'Competitive Profile' ↗

December 03, 2021

More than half of high-dose patients reported a 50% decline in monthly seizures.

Via Investor's Business Daily

Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment ↗

December 03, 2021

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal...

Via Benzinga

The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering ↗

December 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases...

Via Benzinga

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More ↗

November 28, 2021

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week.

Via Talk Markets

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week ↗

November 28, 2021

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.